Charged Alpha Stock Encyclopedia

EchoStar Corporation (ECHO) Q2 2026 — Reported August 3 (Q2 2026, the three months ended June 30, 2026). Total revenue $3.576B, DOWN 4.0% from $3.725B. Diluted EPS $24.12 and net income to EchoStar of $8.462B — but $9.729B of the $9.790B of pre-tax income is a NON-CASH deconsolidation gain booked when DISH DBS and DISH Wireless filed prepackaged Chapter 11 on June 30. Strip it out and pre-tax income was $61M. On August 2, a THIRD subsidiary — Hughes Satellite Systems — filed its own Chapter 11 in Houston. The stock closed at $85.04, UP 1.1% from an $84.09 close, having traded $83.04 to $88.32. Ticker changed from SATS to ECHO on May 26.

The subtraction nobody ran on air: pre-tax income was $9,790.114M and the deconsolidation gain was $9,728,958 thousand — so the entire operating business, four segments and roughly 14 million subscribers, earned $61M pre-tax on $3.576B of revenue, a 1.7% margin. And that $61M still contains a full quarter of DISH Pay-TV, which produced $600.7M of adjusted OIBDA and left the company on June 30. First-half free cash flow was $2.590M.

THE CALL: HOLD (3/5, A GREAT TRADE, ALREADY IN THE PRICE.) — base-case value ~$82.0 vs ~$85.04 today.

KEY METRICS:

- CALL: HOLD 3/5 — fair value ~$82 vs $85.04 (about 4% BELOW). A SUM-OF-THE-PARTS, not a DCF, because Q2 GAAP earnings are a $9.729B non-cash accounting entry, first-half free cash flow was $2.590M, and two of the four segments are now in bankruptcy court. THE BUILD, on 348.5M fully diluted shares (290,451,972 outstanding at 6/30/26 plus ~58M from the 3 7/8% converts): cash after the AT&T close $12.01B + SpaceX stock $11.10B (261.8M shares at the fixed $42.40) + remaining spectrum at carrying value $8.45B + Boost Mobile ~$1.02B (5x annualised adjusted OIBDA of ~$203M) + other investments $0.21B, LESS residual debt and leases $0.21B, deferred tax liabilities $3.41B and an estimated $0.60B of holdco burn to the SpaceX close = $28.6B, or ~$82/share. Range $60–$104 across the two marks we cannot verify.

- THE EARNINGS ARE AN ACCOUNTING ENTRY: pre-tax income $9,790.114M less the $9,728.958M deconsolidation gain = $61.156M — a 1.7% pre-tax margin on $3,576.164M of revenue. Note 3 explains it: on June 30 DISH DBS Corporation and DISH Wireless L.L.C. and their subsidiaries filed prepackaged Chapter 11 petitions in the Southern District of Texas, the Bankruptcy Court assumed control, and under ASC 810 EchoStar deconsolidated them. Those entities carried $11,427.038M of NET LIABILITIES; EchoStar's retained equity in them was marked at $0 because their liabilities exceeded their assets. The gain splits $5,209.671M (DISH DBS) and $6,217.367M (DISH Wireless) less a $1,513.571M deferred tax adjustment, $133.196M of credit-loss allowance and $51.313M of parent guarantees. The 10-Q states it is non-cash AND not currently taxable.

- WHAT ACTUALLY CONTINUES IS ROUGHLY MINUS $20M A QUARTER: Q2 consolidated adjusted OIBDA was $681.195M (vs $279.647M). Of that, $600.656M is Pay-TV, DECONSOLIDATED June 30. $100.199M is Broadband & Satellite (Hughes), which filed Chapter 11 on August 2. Wireless/Boost contributed $50.760M (a genuine swing from -$98.909M) and the abandoned 5G 'Other' segment cost $71.129M. Segment revenue: Pay-TV $2,248.5M, Wireless $929.0M, Broadband & Satellite $316.9M, Other $91.5M. Subscribers at 6/30/26: Pay-TV 6.391M (DISH TV 4.684M, SLING 1.707M), down 241k in the quarter, ARPU $112.39; Wireless 7.375M, DOWN 118k net after ADDING 212k a year ago, gross adds -20.5%, ARPU $38.60 (+3.2%), churn 2.88%; Broadband 622k, down 24.1% year over year.

- THE SPECTRUM LEDGER: AT&T CLOSED, SPACEX HAS NOT. On July 28, 2026 AT&T paid $20.250B in cash for all the 3.45 GHz and 600 MHz licences plus a 99-year Hawaii lease extension; those licences were carried at $16,822.253M. The FCC mandated $2.4B of it into a Wireless Creditor Trust. SpaceX has agreed to pay approximately $20B for the AWS-4 and H-block licences (50 MHz) plus 15 MHz of AWS-3, with up to $11B paid in 261.8M SpaceX Class A shares at a fixed $42.40 after May's 5-for-1 split; the Spectrum Transfer Closing happened May 22, 2026 but the SPECTRUM ACQUISITION CLOSING IS TARGETED FOR NOVEMBER 30, 2027. SpaceX is funding ~$2B of interim debt service on the $9.821B of Seller Notes in the meantime ($828M booked at 6/30/26). EchoStar still owns $8,449.478M of spectrum at carrying value, and has invested over $30B in licences plus $10B of capitalised interest.

- THE CASH BRIDGE AND THE CONTROL QUESTION: cash was $439.988M at June 30 — which is precisely why HSSC, facing $627.283M of 5 1/4% and $750.0M of 6 5/8% notes maturing August 1, 'does not currently have the necessary cash' in the 10-Q's own words, and filed on August 2. Post-AT&T: ~$0.50B of cash and securities + $20.25B, less $2.40B into the FCC trust, less $3.50B redeeming the 11 3/4% notes due 2027, less $2.844B paid to DISH DBS on the 2021 intercompany loan = ~$12.0B. Total debt and finance leases were $17,431.703M at 6/30/26; deferred tax liabilities $3,406.850M. Charles Ergen holds all 131,348,468 Class B shares against 159,103,504 Class A, and the 10-Q's own risk summary says 'We are controlled by one principal stockholder who is our Chairman, President and Chief Executive Officer.' There is no announced plan for the $12B, and in ~40 years he has never paid a dividend or run a meaningful buyback.

- STREET vs US: seven analysts, consensus rating STRONG BUY (6 strong buy / 1 buy / 0 hold / 0 sell per S&P Global as of August 3), average 12-month target $134.86, median $130, low $115, high $161 — 58.6% above the $85.04 close. Citigroup reinstated coverage July 7, 2026 at Buy with a $126 target. We DIFFER sharply and are far more CAUTIOUS on the number: $134.86 implies $47.0B of equity value; we can source $28.6B from the filings. The $18.4B gap is, near enough, the entire remaining spectrum book re-marked at DOUBLE carrying value, plus a large gain on the SpaceX shares above the fixed $42.40, plus the $3.41B of deferred tax never being paid.

What to watch: Bullish: an announced use for the ~$12B of AT&T proceeds that favours shareholders — a buyback, a special dividend or a tender; a third spectrum transaction that marks the remaining $8.449B of licences above carrying value; DISH DBS emerging from the prepackaged plan in 2H 2026 and reconsolidating with real equity value. Bearish: any slippage or renegotiation in the SpaceX Spectrum Acquisition Closing targeted for November 30, 2027 (up to $11B of the consideration is private SpaceX stock at a fixed $42.40); Boost Mobile losing subscribers again in Q3 after shedding 118,000 net in Q2; the $12B being committed to another capital-intensive network build.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

TG Therapeutics, Inc. (TGTX) Q2 2026 — Reported before the open (Q2 2026, the three months ended June 30, 2026). Total revenue $240.3M, +70.3% — a ~$10.6M BEAT. BRIUMVI U.S. net product revenue $227.7M, +64%. But diluted EPS was $0.05 against a Street estimate near $0.31, and operating income FELL to $21.7M from $34.8M — a 9.0% margin against 24.7%. FY2026 total revenue target RAISED to ~$950M from ~$925M, but the BRIUMVI U.S. target moved only $5M, to $890–905M. The stock closed at $46.46, DOWN 10.7% from a $52.03 close, after trading green at $52.65 in the first minutes.

The arithmetic nobody ran: revenue rose $99.187M and cost of revenue rose $22.256M, so gross profit rose $76.931M — a 77.6% incremental margin, BELOW the 82.9% TGTX already earns. R&D rose $63.555M and SG&A rose $26.545M: $90.100M of new operating expense against $76.931M of new gross profit. Operating income therefore FELL $13.169M on a quarter that grew 70%.

THE CALL: HOLD (3/5, THE DRUG IS WINNING. THE MARGIN IS NOT.) — base-case value ~$41.5 vs ~$46.46 today.

KEY METRICS:

- CALL: HOLD 3/5 — fair value ~$41.50 vs $46.46 (about 11% BELOW). Two-step, because $7.8M of net income on $240.3M of revenue and free cash flow that has swung between -$28.7M and +$19.7M across five quarters cannot take an owner-earnings DCF. STEP 1 is the quarterly BRIUMVI curve guidance implies. STEP 2 is a 10-year DCF on ECONOMIC free cash flow (after stock comp, capex, cash tax and interest): base case 18% growth in 2027 fading to 4%, margin 20% to 28%, 10.5% discount, 2.5% terminal = $40.24. Bear $13.56, bull $72.18. Weighted 25/50/25 = $41.56.

- THE INCREMENTAL DOLLAR WENT BACKWARDS: revenue rose $99.187M ($141.148M to $240.335M, +70.3%) and cost of revenue rose $22.256M, so gross profit rose $76.931M — a 77.6% INCREMENTAL margin, below the 82.9% TGTX already earns. R&D rose $63.555M ($31.782M to $95.337M) and SG&A rose $26.545M ($55.585M to $82.130M) — $90.100M of new operating expense against $76.931M of new gross profit, about $1.17 of new cost per new dollar of gross profit. Operating income FELL $13.169M, from $34.843M to $21.674M; margin 24.7% to 9.0%. Net income $7.781M vs $28.187M, DOWN 72%. Fair qualification: $54.6M of the R&D increase is subcutaneous manufacturing and secondary-manufacturer start-up cost.

- THE GUIDANCE RAISE IS SMALLER THAN IT LOOKS: total global revenue went from ~$925M to ~$950M, but the BRIUMVI U.S. target moved only from $885-900M to $890-905M — $5M at the midpoint (0.6%) after a ~$10.6M revenue beat. H1 U.S. BRIUMVI was $422.5M, so the guide implies H2 of $467.5-482.5M against $455.4M for a flat run rate. Management also expects to EXIT 2026 at an ~$1B annualised U.S. run rate (a Q4 near $250M), which implies Q3 at roughly $218-233M — against the $227.7M just delivered, and against a Street Q3 estimate of ~$244.7M.

- THE BALANCE SHEET CHANGED CHARACTER IN MARCH: cash and investments went from $199.511M to $612.253M, but via a five-year $750M senior secured facility from Blue Owl Capital ($250M of old debt repaid, $500M net non-dilutive). Interest expense went from $6.716M to $16.572M, +147% — roughly $66M a year, about 8.8% money, against $7.781M of quarterly net income. Total equity FELL from $648.020M to $604.083M despite $27.558M of H1 net income, because the buyback authorisation was lifted from $100M to $300M; weighted-average basic shares fell from 146.7M to 141.8M.

- THE BULL CASE, AT FULL STRENGTH: BRIUMVI U.S. $227.7M, +64% YoY and +16.9% sequentially from $194.8M. Subcutaneous Phase 1 showed mean bioavailability >60% vs IV, supporting quarterly dosing in a fully enrolled Phase 3 reading out year-end 2026/Q1 2027. The ENHANCE Phase 3 met its primary endpoint — a single 600mg Day 1 infusion replaces the Day 1 + Day 15 regimen. A registration-directed Phase 2 in myasthenia gravis (BRIUMVI maintenance after efgartigimod induction), a Phase 2 in treatment-resistant schizophrenia, and azer-cel Phase 1 data in progressive MS in H2. $612.3M of cash. At $46.46 across 157.3M diluted shares the EV is ~$7.45B — 7.8x the FY2026 revenue target.

What to watch: Bullish: subcutaneous BRIUMVI hitting its Phase 3 at year-end 2026/Q1 2027; a third quarter above $240M in U.S. product revenue (which would prove the flat-quarter guide was conservatism); operating expense holding flat in Q4 as the $54.6M subcutaneous manufacturing spend rolls off. Bearish: U.S. BRIUMVI revenue below $220M in Q3, confirming a genuine deceleration; the $54.6M quarterly subcutaneous charge failing to fall in Q4 (a build cost has to end); any further increase in gross-to-net deductions or in the interest burden on the $754M Blue Owl facility.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Twist Bioscience Corporation (TWST) Q3 FY2026 — Reported before the open (fiscal Q3 2026, the three months ended June 30, 2026). Revenue $118.4M, +23.2% — a ~$3.8M BEAT. Diluted loss per share $0.56 against a Street estimate near $0.50 — a 6-cent MISS. Adjusted EBITDA NEGATIVE $11.3M against NEGATIVE $8.0M — the loss WIDENED $3.3M. FY2026 revenue guidance RAISED to $456–457M from $442–447M. The stock opened at $81.73 (DOWN 10.7% from a $91.55 close), was green inside 15 minutes, hit $101.68 (+11.1%) by late morning, and traded at $95.65, up 4.5% — a 24% intraday range.

The arithmetic nobody ran: revenue rose $22.3M, cost of revenues rose $11.2M, so GROSS PROFIT rose only $11.2M — a 50.0% incremental margin, BELOW the 52.8% Twist already earns. SG&A alone rose $17.3M. The entire incremental gross profit was spent, and $6.2M more with it. That is why adjusted EBITDA got WORSE one quarter before the promised breakeven.

THE CALL: AVOID (3/5, THE COMPANY IS EXCELLENT. THE PRICE IS OUR BULL CASE.) — base-case value ~$51.0 vs ~$95.65 today.

KEY METRICS:

- CALL: AVOID 3/5 — fair value ~$51.00 vs $95.65 (about 47% BELOW). Two-step, because a company with no earnings and negative free cash flow cannot take an owner-earnings DCF. STEP 1 establishes how much REVENUE each breakeven requires at today's cost base: adjusted EBITDA breakeven (the promised one) ~$494M annualised; GAAP operating breakeven ~$708M; TRUE free cash flow breakeven ~$732M — against a $456.5M FY2026 guide. STEP 2 discounts what arrives after: base case 18% growth to FY2031 then 10%, FCF margin (AFTER stock comp and capex) travelling -12% to +20%, 10.5% discount, 18x exit = $47.28. Bear $14.27, bull $96.11. Weighted 25/50/25 = $51.23.

- THE ARITHMETIC NOBODY RAN: revenue rose $22.319M ($96.057M to $118.376M) and cost of revenues rose $11.162M, so gross profit rose just $11.157M — a 50.0% INCREMENTAL gross margin, BELOW the 52.8% Twist already reports. SG&A alone rose $17.339M ($63.370M to $80.709M, +27.4%) on revenue that grew 23.2%. That single line grew 55% MORE than the entire gross profit added. All of the incremental gross profit was consumed and $6.2M more with it — which is exactly why adjusted EBITDA went from -$7.998M to -$11.326M in a quarter billed as the 14th consecutive quarter of growth. SG&A is now 68.2% of revenue against 66.0%.

- TWO BREAKEVENS, ONLY ONE PROMISED: Twist's own adjusted-EBITDA definition excludes stock comp ($50.4M over nine months, 15.1% of revenue) AND all capital spending (~$29M, from PP&E $102.3M to $111.9M against $19.4M of D&A). Adjusted EBITDA of -$38.1M less those two is roughly NEGATIVE $118M of genuine free cash flow in nine months. Real FCF breakeven needs ~$732M of annual revenue at today's cost base — about fiscal 2029 at 18% growth, against a $456.5M guide.

- THE PRICE IS OUR BULL CASE, EXACTLY: at $95.65 across ~62.3M shares the market cap is ~$5,959M and, net of $166.8M of cash with NO DEBT, the enterprise value is ~$5,792M — 12.7x the FY2026 revenue guide and 10.8x our FY2027 estimate. Our BULL DCF at a 10.5% discount rate (24% growth for five years, 13% for five more, FCF margin reaching 26% by FY2036 = $641M) produces $5,821M of enterprise value and $96.11 a share. There is no margin of safety left. Note also that gross margin, which the release quotes as +120bps sequentially, was DOWN 64bps year on year (52.8% vs 53.4%).

- THE BULL CASE, AT FULL STRENGTH: 14 consecutive quarters of sequential growth through the worst life-science tools downturn in twenty years. DNA Synthesis and Protein Solutions $56.6M, +39% YoY and +6% sequentially, pulled by AI-enabled drug discovery; NGS Applications $61.8M, +12% and +8%. Guidance raised so far that the TOP of the old range ($447M) is now BELOW the BOTTOM of the new one ($456M), implying a Q4 growing ~25%. Nine-month gross margin up 165bps to 52.1%. ~369,000 genes shipped vs ~237,000 (+56%), ~2,650 customers vs ~2,480. $166.8M of cash and investments, ZERO debt, $445.7M of equity. This is a valuation call, not a solvency one.

What to watch: Bullish: a genuinely POSITIVE free cash flow quarter (not adjusted EBITDA breakeven — real cash after stock comp and capex); gross margin above 56% (the terminal FCF margin in our model is capped by the gross margin); DNA synthesis sustaining growth above 35% for two more quarters. Bearish: SG&A growing faster than gross profit for a fourth consecutive quarter; the Q4 adjusted EBITDA breakeven being missed or quietly redefined (watch the November language — 'approaching breakeven' is not breakeven); NGS Applications decelerating below 10% growth.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

CNH Industrial N.V. (CNH) Q2 2026 — Reported before the open (three months ended June 30, 2026). Consolidated revenues $4,803M, +2% (FLAT at constant currency); Industrial net sales $4,143M, +3%. Net income $141M vs $217M — DOWN 35%. Diluted EPS $0.11 vs $0.17. Adjusted EPS $0.13 vs a ~$0.10 Street number — a 3-cent BEAT. FY guide narrowed UP to $0.41-$0.46. The stock rose anyway: from a $10.25 close it opened $11.22, hit $12.02 (+17.2%), and sat at $11.08 — UP 8.1%.

The arithmetic nobody ran: Agriculture net sales GREW $29M (to $3,277M) while Agriculture adjusted EBIT FELL $93M (to $170M). That is a decremental margin of MINUS 321% — and it happened with favorable price realization.

THE CALL: HOLD (3/5, THE RECOVERY IS REAL, AND IT IS ALREADY IN THE PRICE) — base-case value ~$12.0 vs ~$11.08 today.

KEY METRICS:

- CALL: HOLD 3/5 — fair value ~$12.00 vs $11.08 (+8.3%), valued in two SEPARATE parts, because a manufacturer with a $28B captive bank cannot take one multiple. (a) INDUSTRIAL Activities on a DCF of INDUSTRIAL free cash flow: $300M/$700M/$1,000M/$1,200M/$1,300M through 2030, 2.0% terminal, 9.5% discount = $14,511M operating EV, less $2,520M of INDUSTRIAL net debt. (b) Financial Services SEPARATELY at 0.85x its $2,923M segment equity = $2,485M; its $22,055M of debt is NOT subtracted. Over 1,241M diluted shares: base $11.66, grid $8.53 (bear) to $15.16 (bull), weighted $11.75. Mid-cycle sum-of-the-parts cross-check: $12.99.

- AGRICULTURE GREW REVENUE AND LOST A THIRD OF ITS PROFIT: net sales $3,248M to $3,277M (+$29M) while adjusted EBIT went $263M to $170M (-$93M). A decremental margin of MINUS 321% — three dollars of operating profit destroyed per extra dollar of revenue — and it happened WITH favorable price realization. Margin fell 290bps to 5.2% from 8.1%, on South America volumes, unfavorable North America/EMEA mix, tariffs, higher SG&A and R&D (6.1% of sales) and weaker JV results. Industry volumes: NA tractors under 140HP -16%, over 140HP -17%, combines -7%; SA combines -29%.

- THE CASH FLOW NOBODY PRICED: first-half free cash flow of INDUSTRIAL Activities was NEGATIVE $439M against -$116M a year ago, versus a full-year guide of PLUS $200-400M — so the back half must produce $639-839M. Last year's back half did $629M, off a first half that was $323M better. Operating cash flow fell from $772M to $145M in the quarter. Inventories ROSE $520M to $5,171M in a destocking year. And dividends declared per share went $0.470 (2024) to $0.250 (2025) to $0.100 (2026) — cut 79% in two years, the second cut made going INTO the recovery management says starts in 2027.

- THE DOMINO THAT FALLS LAST: Financial Services earned $71M of the quarter's $141M of consolidated net income — HALF the profit on 14% of revenue — while its own credit deteriorated. Receivables 30+ days past due 4.4% vs 3.9%, which CNH attributes to farmer economics in South America. Retail originations $2,740M to $2,531M; managed portfolio down $0.7B to $28.0B; segment net income -18% on higher Brazil risk costs. Mind the basis trap: consolidated revenue of $4,803M contains $656M of lender income — INDUSTRIAL net sales were $4,143M. Consolidated net debt is $23.35B; INDUSTRIAL net debt is $2.52B.

- THE OTHER SIDE, AND THE STREET: the bull case is real. Construction net sales +12% into a global industry +17%, with demand up in EVERY region; the guidance floor raised from $0.35 to $0.41; dealer destocking nearly done, fleets aging, used-vs-new pricing rebalancing. Agriculture earned a 14.5% margin as recently as 2023 against ~5.25% guided now, so mid-cycle EPS is ~$1.11 against $0.44 — about 10x. Street: Buy (9 buy / 4 hold / 1 sell, 14 analysts), target $13.29 average, $12.63 median, range $10.50-$16.00 (+20.0%). We AGREE on direction and are more CAUTIOUS on size: $13.29 reads as an UNDISCOUNTED mid-cycle number. Reverse the DCF and $11.08 already assumes a 12.0% mid-cycle Agriculture margin against 5.2% today.

What to watch: Bullish: Agriculture adjusted EBIT margin above 7% in any quarter of 2027 (the recovery arriving in the P&L, not the order book); North American large-tractor industry volume turning POSITIVE (it was -17%); full-year Industrial free cash flow above $400M. Bearish: Financial Services 30-day delinquencies above 5.0% (4.4% now vs 3.9%); another dividend cut or the $0.10 not restored in 2027; Agriculture margin guidance cut below 5.0%.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Krystal Biotech, Inc. (KRYS) Q2 2026 — Reported before the open (three months ended June 30, 2026). Revenue $119.222M, +24.1%, just UNDER a ~$120.9M Street number. Diluted EPS $1.79 vs ~$1.70 — a BEAT. Operating income $58.417M at a 49.0% margin. The stock fell anyway: from a $341.12 close it opened at $320.70, hit $297.73, and sat at $299.04 — DOWN 12.3%.

The framing nobody applied: the 10-Q's geographic table, which the press release does not print, says UNITED STATES revenue was $91.633M against $96.042M — DOWN 4.6%, while Europe ($19.283M) and Japan ($8.306M) were both ZERO a year ago.

THE CALL: AVOID (4/5, A SUPERB BUSINESS AT A PRICE THAT NEEDS THE WHOLE PIPELINE TO WORK) — base-case value ~$153.0 vs ~$299.04 today.

KEY METRICS:

- CALL: AVOID 4/5 — fair value ~$153 vs $299.04 (-48.8%), valued in two SEPARATE parts. VYJUVEK annuity: 2030 revenue $598M (US held FLAT at ~$367M despite the decline; ex-US more than doubling to ~$231M), 5.4% COGS, 21% tax, 0.5% terminal, 9.5% discount = $1,981M EV + $1,102.9M net cash over 30.657M shares = ~$100/sh. Plus the pipeline as a separate risk-adjusted option, $1,380M = $45/sh. Grid: bear $134 / base $146 / bull $188 — ALL NINE cells below the price; even the bull at 8% is $211.

- US REVENUE WENT DOWN: the 10-Q geographic table reads US $91.633M vs $96.042M (-4.6%), Europe $19.283M vs ZERO, Japan $8.306M vs ZERO. Six months: US $179.122M vs $184.225M (-2.8%) — down year on year in BOTH quarters of 2026. Nor is ex-US compounding: derive Q1 2026 (US $87.489M, Europe $20.677M, Japan $8.191M) and Europe fell 6.7% sequentially, ex-US -4.4%, in the FIRST YEAR of a launch. Revenue rose 2.5% QoQ only because the US bounced off a weak Q1.

- PENETRATION MATH: 730+ US reimbursement approvals and 640+ prescribers against ~894 US patients estimated eligible in a peer-reviewed economic evaluation. List price $24,250/vial x ~26 vials = ~$630k a patient-year; US revenue annualises to $367M = $502k per approval. So 65-82% of the eligible US pool is already paid for. Management's fair counter — a label update with more dosing flexibility, plus accrued rebates up $25.8M vs $14.8M — still says net revenue per patient is FALLING.

- PIPELINE, PRICED HONESTLY: KB803 (corneal abrasions in DEB, registrational, top-line 4Q 2026) ~$120M peak x 55% = $190M. KB801 (neurotrophic keratitis, registrational) ~$450M x 40% = $440M. KB407 (cystic fibrosis, 5-pt open label, FDA alignment 4Q 2026) ~$700M x 20% = $300M. KB707 (inhaled NSCLC, 31% ORR with pembrolizumab) ~$900M x 15% = $250M. KB408/KB111/Gorlin/KB304 $200M. Total $1.38B = $45/sh; the market pays $6.08B = $198/sh.

- THE OTHER SIDE, AND THE STREET: a superb business — 94.6% gross margin, 49.0% operating margin, $144.458M of six-month free cash flow, $1,102.9M of cash and investments, NO debt, no competitor, $965.9M since launch. Street: Buy — unanimously, 17 buy / 0 hold / 0 sell — target $364.50 avg, $342.00 median, range $300-$474 (+21.9%); even the LOWEST target is above the price. We ALIGN on the asset, DIFFER on what has been added to it, and are far more CAUTIOUS.

What to watch: Bullish: KB803 hitting its endpoint in 4Q 2026 (the first registrational readout since VYJUVEK — it lifts the odds on KB801, KB407 and KB707 at once); US revenue growing two straight quarters; or German/French pricing settling at or above launch price. Bearish: a third straight quarter of US decline; EU pricing settling BELOW launch; or KB803 missing.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Tyson Foods, Inc. (TSN) Q3 FY2026 — Reported before the open August 3, 2026 (fiscal Q3 FY2026, the thirteen weeks ended June 27, 2026). Adjusted EPS $0.99 (+9%) vs a ~$0.98 consensus. Adjusted operating income $547M (+8%) at a 3.9% margin. But sales were FLAT at $13,868M against a Street number nearer $14.07B — a miss — and gross margin fell to 6.6% from 8.2%. The stock opened at $55.89 (-3.6%), traded as low as $54.60 (-5.8%), then reversed to close at $59.22, UP 2.2% on the day and up 8.5% from the low.

The framing nobody applied: everyone treats Tyson as a beef-trough recovery story. Run the company's own segment guidance instead. Chicken is guided to $1.90-2.05B of adjusted operating income on roughly $17.1B of sales — an ~11.5% full-year margin, its best in the modern era, bought with cheap corn and soybean meal. Beef is guided to LOSE $500-650M. Add the five segments and corporate costs and total adjusted operating income is $2.1-2.3B. So today's earnings are not depressed. They are one segment at a cyclical PEAK funding another at a trough, and the two very nearly cancel. Normalise all five and we get $2,495M of mid-cycle operating income against a $2,200M guided midpoint — thirteen percent of uplift, not a doubling. Second unwritten line: trailing adjusted EBITDA of $3,529M sits $971M above GAAP EBITDA of $2,558M, and the largest single add-back is LEGAL CONTINGENCY ACCRUALS — $664M in the last twelve months, $738M in FY2025, $269M in the first nine months of FY2026. They recur every year, and $98M of this quarter's was booked as a reduction to SALES.

THE CALL: HOLD (3/5, A GOOD BUSINESS AT A FAIR PRICE — AND CHICKEN IS NOT A BASE, IT IS A PEAK) — base-case value ~$62.0 vs ~$59.22 today.

KEY METRICS:

- CALL: HOLD 3/5 — fair value ~$62 vs $59.22 (+4.7%). Owner-earnings DCF on MID-CYCLE segment operating income. Mid-cycle bridge: Chicken $1,450M (8.5% margin, down from an ~11.5% guide), Beef +$300M (up from a guided -$575M), Pork $250M, Prepared Foods $1,300M, International $175M, corporate and amortisation -$980M = $2,495M, against a $2,200M guided midpoint. Less $365M net interest, taxed at the guided 25% = $1,598M; plus $1,430M D&A, less $1,200M normalised capex and working capital = $1,660M of owner earnings. 4% for 5 years, 3% for 5 more, 2.5% terminal at 8.5%: EV $30,765M less $7,266M net debt / 352M shares = $67. Nine-cell grid: bear $22 / base $67 / bull $103 at 8.5%; FIVE of nine cells clear the price. Weighted 25/50/25 = $64.60, less $2.24 a share for recurring legal accruals = ~$62. Reverse DCF: $59.22 implies just 2.45% perpetual growth on mid-cycle owner earnings.

- CHICKEN IS AT A PEAK, NOT A BASE: Chicken earned $488M of adjusted operating income on $4,255M of sales — an 11.2% margin against 10.6% — while chicken sales grew only 0.8%, so essentially none of the profit growth was volume or price. Seven consecutive quarters of growth. FY2026 guidance is $1.90-2.05B, an ~11.5% full-year margin, in a year the USDA projects chicken production rises about 3%. Vertically integrated chicken at eleven and a half percent is what cheap grain looks like, not a moat. Chicken alone is guided to earn MORE than the entire company nets after corporate costs of $950-975M.

- BEEF, QUANTIFIED: sales $5,391M vs $5,603M, with volume DOWN 15.9% while average price rose 12.1% — a supply squeeze, not weak demand. The USDA projects domestic beef production falls about 3% in FY2026. Adjusted operating loss $138M, a -2.6% margin, WORSE than last year's -2.1%. Over nine months it is -$483M against -$223M: the loss has more than doubled. FY2026 guide is a loss of $500-650M. Beef simply returning to breakeven would be worth about $1.22 of EPS against our ~$3.86 FY2026 adjusted estimate.

- THE $664 MILLION ADJUSTED OUT EVERY YEAR: trailing adjusted EBITDA $3,529M against GAAP EBITDA $2,558M — a $971M gap, nearly 38%. The largest single component is legal contingency accruals: $664M added back over twelve months, $738M in FY2025, $343M in 9M FY2025, $269M in 9M FY2026. Four periods, four large accruals. And $98M of this quarter's was recognised as a reduction to SALES, which is how flat sales become 'up 0.6% excluding the accrual'. Separately, capex is guided at $0.7-0.9B against D&A of about $1.4B a year — net PP&E fell from $9,204M to $8,789M in nine months, and normalising capex to $1.2B takes the free-cash-flow yield from 7.1% to about 5.2%.

- THE HONEST OTHER SIDE, AND THE STREET: Prepared Foods is guided to $1.3-1.35B at a 13% margin — more than half the total company guide from 18% of the sales — and at 13x operating income is worth roughly $17B against a $28.4B enterprise value. Total debt fell $824M in nine months to $8,006M; net debt is 2.1x adjusted EBITDA, unchanged through the worst beef market in memory; liquidity is $4.0B. The dividend was raised to $0.510 a quarter (about $2.04 annualised, a 3.4% yield) and is covered 2.1x by guided free cash flow of $1.3-1.7B. TSN trades at about 15.3x our FY2026 adjusted EPS estimate of $3.86 and 7.9x guided adjusted EBITDA. Street: Buy (15 buy / 14 hold / 1 sell, 30 analysts), average target $68.67, median $65.00, range $63-$78, implying +16.0% — and even the LOWEST target is above the price. We ALIGN on direction, DIFFER on size, and are more CAUTIOUS.

What to watch: Bullish: heifer retention showing up in USDA cattle inventory data, which is the earliest honest signal the herd is rebuilding and would pull our mid-cycle Beef assumption forward by years; Prepared Foods printing above the $1.35B top end, because branded operating income deserves a higher multiple than commodity operating income; or capital spending rising back toward depreciation while free cash flow holds. Bearish: the Chicken margin rolling over on a grain move — that segment is guided to earn more than the whole company nets, so two points of margin is roughly $340M; Beef guidance cut again in November after a nine-month loss that has already more than doubled; or legal contingency accruals continuing at $250M or more a year.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Marriott International, Inc. (MAR) Q2 2026 — Reported before the open August 3, 2026 (calendar Q2, quarter ended June 30). Adjusted diluted EPS $3.19 (+20.4%) vs a ~$3.08 consensus. Adjusted EBITDA $1,592M (+13%). But total revenues were $7,071M against a ~$7.19B Street number — a miss — and REPORTED operating income FELL 1% to $1,229M. The company raised full-year RevPAR growth to 3.0-3.5% and full-year adjusted EPS to $11.64-11.81, yet guided Q3 adjusted EPS to $2.74-2.82 against a ~$2.86 consensus and cut net rooms growth to the LOW END of 4.5-5%. The stock fell 6.8% to $347.33.

The framing nobody applied: gross fee revenues grew 13%, but franchise fees grew 18.9% ($860M to $1,023M) on what Marriott itself calls 'primarily higher co-branded credit card fees', while BASE MANAGEMENT FEES — the purest hotel line in the P&L — grew 0.9% ($340M to $343M). Worldwide RevPAR was +3.4% and net rooms +4.5%. In May the outlook said in writing it 'does not include any impact from the renegotiation of our U.S. co-branded cards'; in August it 'includes the expected partial year incremental impact of the new terms' — and the full-year gross fee guide went up exactly $100M at both ends. Second unwritten line: cost reimbursement revenue of $5,058M against $5,100M of reimbursed expenses is MINUS $42M, against PLUS $58M a year ago, and adjusted EPS deletes both lines entirely.

THE CALL: SELL (3/5, A GREAT BUSINESS, A CREDIT-CARD-FLATTERED QUARTER, AND A PRICE THAT NEEDS PERFECTION) — base-case value ~$245.0 vs ~$347.33 today.

KEY METRICS:

- CALL: SELL 3/5 — fair value ~$245 vs $347.33 (-29.5%). Owner-earnings DCF on FEE-based free cash flow. FY2026E FCF $2,900M (FY2025 actual: $3,212M operating cash flow less $604M capex = $2,608M, per SEC XBRL). Base case 10% for 5 years, 6% for 5 more, 3.0% terminal at 8.5%: PV yrs 1-5 $15,113M + yrs 6-10 $14,489M + terminal $51,769M = $81,371M EV, less $16,400M net debt, / 264.5M diluted shares = $246. Nine-cell grid (bear/base/bull x 8.0%/8.5%/10.0%): NOT ONE cell reaches $347.33 — the most generous, bull at 8%, is $338. Weighted 25/50/25 = $245. Reverse DCF: the price needs 14.5% FCF growth for five years and 8.7% for five more, or 4.8% terminal growth forever, or a 7.2% discount rate. Marriott has NEGATIVE book equity from a decade of buybacks, so no P/B framing is used.

- THE CREDIT CARD DID THE WORK: gross fee revenues $1,578M (+13%), but franchise fees $860M to $1,023M (+18.9%) driven 'primarily by higher co-branded credit card fees', while base management fees went $340M to $343M (+0.9%) and incentive fees $200M to $212M (+6%). Worldwide RevPAR +3.4% (U.S. & Canada +5.0%, international -0.5%), net rooms +4.5%. The proof is in the guidance: May's outlook explicitly EXCLUDED the U.S. co-branded card renegotiation and guided FY gross fees to $5,925-5,985M; August's INCLUDES it and guides $6,025-6,055M — up exactly $100M at both ends.

- THE LINE ADJUSTED EPS DELETES: cost reimbursement revenue $5,058M against reimbursed expenses $5,100M = MINUS $42M, versus $4,932M against $4,874M = PLUS $58M a year ago — a $100M swing. Six months: minus $134M vs minus $9M. Both lines are removed IN FULL to reach adjusted results, which is exactly why REPORTED operating income fell 1% ($1,236M to $1,229M) while ADJUSTED operating income rose 12% ($1,186M to $1,329M), and why reported EPS is $2.90 against an adjusted $3.19. Also in reported: a $68M impairment on a U.S. hotel sale (adjusted out) and a $27M property litigation accrual worth $0.08/share (not adjusted out).

- THE RAISE IS PARTLY ARITHMETIC: adjusted net income +15.9% ($728M to $844M) but adjusted EPS +20.4% ($2.65 to $3.19) — diluted shares fell 3.7%, 274.7M to 264.5M. Marriott bought 3.0M shares for $1.1B in the quarter and 6.2M shares for $2.2B year-to-date, with FY capital return guided above $4,500M — about 4.9% of the $91.5B market value in one year. Total debt rose to $16.9B against $0.5B of cash. Three guide lines went the WRONG way: net rooms growth cut to the LOW END of 4.5-5%; owned/leased net cut $40M to $175-185M; investment spending raised $200M to $1,250-1,350M. And Q3 adjusted EPS is guided $2.74-2.82 against a ~$2.86 consensus.

- THE HONEST OTHER SIDE, AND THE STREET: a record development pipeline of 4,186 properties and ~629,000 rooms (up nearly 7%, 44% under construction), record first-half global signings, Marriott Bonvoy past 295 million members, a 66% adjusted operating margin on $2,013M of adjusted revenue, and U.S. & Canada RevPAR +5.0% with company-operated luxury RevPAR $357.49 (+9.5%) and The Ritz-Carlton +9.8%. Street: Hold (23 buy / 28 hold / 1 sell, 52 analysts), average target $393.50, range $350-$449, implying +13.3%. We ALIGN on the business, DIFFER on price, and are far more CAUTIOUS.

What to watch: Bullish: base management fees re-accelerating from 0.9% to mid single digits, which is the cleanest read on underlying hotel economics in the filing; the Middle East normalising off a 43% RevPAR decline, with over half the pipeline international; or evidence the JPMorgan Chase / American Express card repricing is a recurring escalator rather than a one-time step. Bearish: the November 3 print at the low end of the $2.74-2.82 guide with U.S. RevPAR decelerating below 4%; the reimbursement gap widening again beyond minus $42M; or net rooms growth slipping below 4.5%, the line already quietly cut to the low end of its range.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Carpenter Technology Corporation (CRS) Q4 FY2026 — Reported before the open July 30, 2026 (fiscal Q4 and fiscal year ended June 30). Net sales $851.0M (+12.6%), but +9.0% to $679.7M excluding the raw-material surcharge. Operating income a record $206.9M (+36.7%); diluted EPS $3.23 (+46.2%) vs a $3.09 consensus. SAO adjusted operating margin a record 37.8% vs 30.5% — an 18th consecutive quarter of expansion. FY2026 operating income $702.0M, the most profitable year in company history. FY2027 guided $850-880M (+21-25%); FY2029 target $1.2-1.3B. The stock still closed down 5.1% at $503.71, and was $533.91 on August 3.

The framing nobody applied: FY2026 net sales ex-surcharge rose $181.4M and Aerospace & Defense alone rose $217.7M. Aerospace contributed 120% of the growth — the other five end markets together shrank $36.3M. Medical, the bull case's counter-cyclical diversifier, fell 24.2% for the year. Second unwritten line: the record margin was not price. SAO shipped 22.6% more pounds while revenue per pound ex-surcharge FELL 9.6%. Absorption, not pricing power.

THE CALL: SELL (4/5, AN EXCEPTIONAL BUSINESS AT A PRICE THAT NEEDS THE NEXT DECADE TOO) — base-case value ~$300.0 vs ~$533.91 today.

KEY METRICS:

- CALL: SELL 4/5 — fair value ~$300 vs $533.91 (-43.8%). DCF on company guidance: FY2027 adj. FCF guided $400-430M, FY2028 ~$665M, FY2029 ~$904M as brownfield capex rolls off. PV of FY2027-31 $3,003M + $11,548M terminal (3.0% growth, 9% discount) = $14,550M EV, less $297.4M net debt, / 50.4M diluted shares = $283. At 9%: bear $198 / base $283 / bull $436, weighted 25/50/25 = $300. Only one of nine cells clears today's price, and it needs the upside case AND an 8% rate on a cyclical.

- AEROSPACE WAS 120% OF THE GROWTH: FY2026 net sales ex-surcharge rose $181.4M; Aerospace & Defense alone rose $217.7M ($1,440.7M to $1,658.4M, +15.1%). The other five end markets together went BACKWARDS $36.3M (-4.0%, $905.4M to $869.1M). Medical fell 24.2% for the year ($296.1M to $224.3M) and 29.6% in Q4 ($76.8M to $54.1M); Transportation -10.8%, Distribution -8.1%. A&D is now 65.6% of sales vs 61.4%. Carpenter is CONCENTRATING, not diversifying — the reverse of the bull framing.

- THE RECORD MARGIN WAS NOT PRICE: incremental operating margin on ex-surcharge revenue was 99% for the quarter (sales +$56.0M, op income +$55.5M) and 99% for the year (+$181.4M/+$180.2M). But SAO shipped 22.6% more pounds while net sales ex-surcharge PER POUND fell 9.6% ($11.69 to $10.57); total cost per pound fell 13.0% ($10.82 to $9.41) and operating income per pound rose 12.2%. Fixed-cost absorption, not pricing power — it reverses as fast as it repeats.

- CASH CONVERSION FALLS AS EARNINGS ACCELERATE: adj. FCF was 54.7% of adj. operating income in FY2025, 51.6% in FY2026 ($362.3M on $702.0M), and the FY2027 guide of $400-430M on $865M is 48.0% — guided FY2027 capex is $355-375M vs $242.7M spent and ~$150M depreciation, ~2.5x D&A. At $533.91 that is 64.8x guided FY2027 FCF, 50.8x trailing EPS of $10.52 and 32x trailing EBITDA. Receivables +22.0% to $701.9M on 8.6% sales growth; DSO 73 to 82 days.

- THE HONEST OTHER SIDE, AND THE STREET: 18 straight quarters of SAO margin expansion, adj. operating income up 5x in 3 years ($133M FY23 to $702.0M FY26), net debt $297.4M (~0.35x EBITDA), and an FY2029 target management calls 'not the peak'. On trailing earnings CRS at 50.8x is the CHEAPEST of the aero-materials complex (Howmet ~66x, ATI ~63x): de-rating risk is sector-wide. Street: Buy (14/6/1), consensus $550.60, median $600.00, range $425-$620. We ALIGN on the business, DIFFER on price.

What to watch: Bullish: Medical inflecting back to growth repairs the diversification case; brownfield commissioning on time in early FY2028 with capex falling toward the ~$150M depreciation line, which alone takes FY2029 FCF toward $1B; or a raise above the $1.3B FY2029 top end. Bearish: the Oct 22 print at the low end of the guided $195-200M with Medical still falling; capex above $375M or a brownfield slip; or receivables — DSO went 73 to 82 days.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

DexCom, Inc. (DXCM) Q2 2026 — Reported after the close July 30, 2026 (quarter ended June 30). Revenue $1,308.4M, +13.1% reported and +12% organic. US $933.4M (+11.0%); international $375.0M (+18.6%). GAAP operating margin 24.3% vs 18.4% — operating income +49.7%. GAAP diluted EPS $0.64 (+42%); non-GAAP $0.70 (+46%). Adjusted EBITDA $421.3M, 32.2% of revenue. FY26 revenue guidance raised at the midpoint to $5.18-5.25B, with gross margin, operating margin and EBITDA margin guidance all raised. The stock closed +11.95% the next session at $83.45 — a new 12-month closing high.

The framing nobody applied: revenue rose $151.3M year over year and cost of sales rose $10.1M. That is a 93% incremental gross margin, and it is why operating income grew 49.7% on 13.1% revenue growth. Second unwritten line: the effective tax rate fell from 25.4% to 21.5% because the Malaysia tax holiday commenced. Two structural changes, one factory, neither in the headline.

THE CALL: HOLD (4/5, A REAL INFLECTION, AND A PRICE THAT ALREADY OWNS IT) — base-case value ~$83.0 vs ~$83.45 today.

KEY METRICS:

- CALL: HOLD 4/5 — fair value ~$83 vs $83.45 (-0.5%). FY2026 free cash flow base ~$1.0B (guided $5.215B revenue at the guided 31.75% adjusted EBITDA margin = $1.656B, less ~$285M cash tax at the new 21.5% rate, less ~$340M capex with Ireland starting up; H1 already delivered $633.5M). DCF at 14% for five years then 8%, 2.5% terminal, 9.0% discount = $30.7B EV plus $704M net cash / 380M diluted shares = $83. Probability-weight the column 25/50/25 and you get $82.

- THE COST LINE IS THE STORY: revenue +$151.3M ($1,157.1M to $1,308.4M) while cost of sales rose just $10.1M ($468.3M to $478.4M, +2.2%). Gross profit +$141.2M — a 93% incremental gross margin. Across H1: revenue +$307.2M, cost of sales +$4.7M. GAAP gross margin 59.5% to 63.4%; non-GAAP 60.1% to 64.1%. The 10-Q names the driver: G7 15-Day benefits, manufacturing efficiencies, higher production volumes and 'better absorption of fixed costs'. The 2024-25 margin collapse was overhead against too few units, not price.

- THE TAX LINE NOBODY READ: effective tax rate 21.5% vs 25.4%, 'primarily attributable to the commencement of our Malaysia tax holiday'. Tax was $68.4M on $317.5M pre-tax; at the old rate it would have been ~$80.6M, so the holiday was worth ~$12M — about $0.03 of the $0.19 GAAP EPS increase. A manufacturing tax holiday runs for years, on the same plant whose fixed costs just started absorbing. The offset: other income went +$28.5M to -$0.8M (-$11.1M interest income, -$10.3M FX, -$9.6M equity losses), so pre-tax income grew 31.7% against 49.7% for operating income.

- THE HONEST BEAR CASE: the RAISED full-year midpoint of $5.215B against H1 of $2,500.3M implies $2,714.7M in H2 versus $2,468.9M a year ago — about +10%, against +14.0% in H1. Only ~$15M of that is the flagged FX headwind. And Q2 operating cash flow FELL 11% to $269.2M even as operating income rose 50%, on a $101.6M H1 inventory build ($629.1M to $726.4M) ahead of Ireland and the 15-day conversion.

- GLP-1 AND CASH: in the CONNECT randomised trial, type 2 non-insulin patients on DexCom improved A1C 1.6% over six months (0.9% vs control) with 97% median wear — and management stated the LARGEST relative A1C improvement was in the cohort using GLP-1 therapies ALONE. H1 free cash flow $633.5M vs $305.7M ($794.8M operating cash less $161.3M capex, capex DOWN 11%). $600.0M of buyback in Q2 (8.6M shares) out of a new $1.00B authorisation; diluted shares 408.2M to 390.1M. Street: Buy, $89.23 consensus (+6.9%), range $64-$105 — we ALIGN on the business, CAUTIOUS on price.

What to watch: Bullish: a positive CMS decision on type 2 non-insulin coverage before year end (25 million Americans, roughly half of Medicare age); the G7 15-Day conversion passing 50% of the US base by year end, which becomes the 2027 starting point; second-half non-GAAP gross margin holding above 64% through the Ireland start-up. Bearish: second-half revenue growth below 10% on the Oct 29 print, which would turn the guide from conservatism into real deceleration; a second consecutive quarter of falling operating cash flow, which would say the $101.6M inventory build is demand and not preparation; or the US direct line, already down 2.7%, turning out to be the leading edge of price competition.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Amphenol Corporation (APH) Q2 2026 — Reported before the open July 29, 2026 (quarter ended June 30). Net sales $8,758.1M, +55% in dollars and +30% ORGANIC. GAAP diluted EPS $1.37 (+59%); adjusted $1.35 (+67%). GAAP/adjusted operating margin 29.5%/29.8%, both records. Record orders of $10.7B for a 1.23:1 book-to-bill. Free cash flow $1,205.5M — up just 7.5%. Q3 guided to $9.3-9.4B and $1.40-1.42. The stock had fallen 8.6% into the print, then closed +4.5% on the day and finished the week at $160.70, +11.7%.

The framing nobody applied: adjusted EPS grew 67% and free cash flow grew 7.5%. Cash conversion fell from 109% of adjusted net income to 69%. And Communications Solutions is now 62% of sales and 67% of segment operating profit — Amphenol's diversification argument is largely gone.

THE CALL: HOLD (3/5, A RECORD QUARTER, AND A PRICE THAT ALREADY OWNS THE DECADE) — base-case value ~$135.0 vs ~$160.7 today.

KEY METRICS:

- CALL: HOLD 3/5 — fair value ~$135 vs $160.70 (-16%). Normalised 2027 owner earnings ~$7.5B (~$40B of sales at a 29% adjusted operating margin, less $0.85B interest, taxed at the new 27.0% rate = ~$7.8B adj. net income; plus $1.7B D&A and $0.2B stock comp, less $1.6B capex and a $0.9B working-capital build). DCF at 11% for five years then 6%, 3% terminal, 9.0% = $180B EV less $13.5B net debt / 1,289.2M diluted shares = $129. Probability-weight the column 25/50/25 and you get $134.

- THE CASH DID NOT FOLLOW THE EARNINGS: Q2 free cash flow $1,205.5M vs $1,121.3M — up 7.5% — while adjusted diluted EPS grew 67% and adjusted net income grew 69% ($1,030.1M to $1,745.7M). Conversion fell from 109% of adjusted net income to 69%; H1 fell from 93% to 65%. Working capital consumed $1,176.4M in the half: receivables $4,717.1M to $6,790.1M, inventory $3,424.9M to $4,551.6M. FY2025 was ~103% ($5,374.7M OCF less $996.6M capex).

- THE DIVERSIFICATION IS OVER: Communications Solutions is ~62% of sales (51.5% a year ago) and $1,808.3M of $2,686.5M of segment operating income — 67%, against 59%. The 10-Q names the driver twice: outsized organic growth in IT datacom 'with particular strength in AI-related applications'. Segment organic growth was +42% / +22% / +13% and margins 33.6% / 30.1% / 21.0%.

- THE TWO ONE-TIMERS POINT OPPOSITE WAYS — AND THIS CUTS BULLISH: an $80.0M IEEPA tariff recovery ($0.04/sh) sits INSIDE both GAAP and adjusted operating income, while $80.5M of excess tax benefit on stock comp ($0.06/sh of real cash tax saved) is EXCLUDED. Clean of the tariff refund, Q2 was ~$1.31 — and Q3 is guided to $1.40-1.42 explicitly assuming NO further recoveries, so the clean sequential step is ~7-8%, bigger than the headline implies.

- THE BALANCE SHEET CHANGED IN SIX MONTHS: cash $11,130.6M to $4,729.4M; debt $15,502.0M to $18,811.3M (net debt $13,392.2M); interest expense 2.6x to $213.7M. Goodwill $10,575.4M to $17,554.7M and intangibles $2,241.4M to $5,288.9M — together $22,843.6M, 51% of assets and 1.47x book equity. The adjusted tax rate was permanently raised to 27.0% from 24.5% after China assessed $290M on prior years. Street: Buy, $192.33 (+19.7%) — we ALIGN on the business and DIFFER on price.

What to watch: Bullish: free cash flow conversion back above 90% in H2 (that alone lifts our base to ~$8.5B and fair value toward $150); another book-to-bill above 1.2 on the Oct 28 print; or a further CommScope accretion upgrade after they already doubled it from $0.15 to $0.30. Bearish: a book-to-bill below 1.0 — at 62% of sales in one segment that is where a digestion phase shows first; any further Chinese tax assessment after the $290M already taken on prior years; or adjusted operating margin coming off 29.8% once the $80M of tariff recoveries stops.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.